
    
      Patients from Phase 3 study may continue into an open label, long term safety extension.
      Patients will be admitted into the study only after a written informed consent has been
      obtained and not missing more than 1 visit of Visits 3, 4 or 5 in the phase 3 study. Eligible
      patients for enrollment will apply the study product, S5G4T-1, daily for up to 36 weeks to
      complete long term usage of the drug for 24 to 48 weeks.
    
  